ImmunityBio, Inc. (IBRX)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS45256X1037
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by ImmunityBio, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 15:18. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 22 Feb 2027 08:00 | -0.04 | — | — | Upcoming |
| 09 Nov 2026 07:00 | -0.05 | -0.09 | -84.8% | Miss |
| 04 Aug 2026 07:00 | -0.08 | -0.22 | -175.0% | Miss |
| 07 May 2026 07:00 | -0.07 | -0.08 | -20.0% | Miss |
| 23 Feb 2026 07:00 | -0.10 | -0.06 | +37.9% | Beat |
| 04 Nov 2025 22:00 | -0.10 | -0.07 | +30.0% | Beat |
| 05 Aug 2025 07:00 | -0.10 | -0.10 | 0.0% | In line |
| 12 May 2025 06:00 | -0.14 | -0.15 | -7.1% | Miss |
| 03 Mar 2025 07:00 | -0.13 | -0.08 | +38.5% | Beat |
| 12 Nov 2024 07:00 | -0.18 | -0.12 | +33.3% | Beat |
| 12 Aug 2024 08:00 | -0.15 | -0.20 | -33.3% | Miss |
| 09 May 2024 17:00 | -0.16 | -0.20 | -25.0% | Miss |
| 19 Mar 2024 16:00 | -0.18 | -0.38 | -111.1% | Miss |
| 09 Nov 2023 06:00 | -0.18 | -0.19 | -5.6% | Miss |
| 08 Aug 2023 16:00 | -0.23 | -0.32 | -36.2% | Miss |
| 11 May 2023 06:00 | -0.27 | -0.27 | 0.0% | In line |
| 01 Mar 2023 17:00 | -0.16 | -0.27 | -63.6% | Miss |
| 09 Nov 2022 06:00 | -0.21 | -0.28 | -30.2% | Miss |
| 08 Aug 2022 16:00 | -0.24 | -0.24 | 0.0% | In line |
| 10 May 2022 16:00 | -0.22 | -0.26 | -18.2% | Miss |
| 01 Mar 2022 17:00 | -0.21 | -0.23 | -9.5% | Miss |
| 12 Nov 2021 16:00 | -0.20 | -0.22 | -10.0% | Miss |
| 12 Aug 2021 16:00 | -0.12 | -0.23 | -91.7% | Miss |
| 14 May 2021 16:00 | -0.41 | -0.21 | +48.8% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 113.3M | +668.3% | -351.4M | -310.2% | -0.38 | +38.7% | -309.2M |
| 2024 | 14.7M | +2,270.6% | -413.6M | -2,804.8% | -0.62 | +46.1% | -398.1M |
| 2023 | 622K | +159.2% | -583.2M | -93,761.4% | -1.15 | -10.6% | -397.3M |
| 2022 | 240K | — | -416.6M | -173,569.6% | -1.04 | — | -436.9M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 09 Nov 2026 – 12 Nov 2026 In progress | 7.22 | 7.35 | 6.00 | 6.07 | -29.70% | 97,856,200 | |
| 02 Nov 2026 – 06 Nov 2026 | 8.32 | 8.95 | 7.88 | 8.64 | +4.16% | 46,865,900 | |
| 26 Oct 2026 – 30 Oct 2026 | 8.23 | 8.94 | 7.75 | 8.29 | +0.85% | 44,825,400 | |
| 19 Oct 2026 – 23 Oct 2026 | 9.19 | 9.70 | 8.02 | 8.22 | -10.46% | 63,873,800 | |
| 12 Oct 2026 – 16 Oct 2026 | 10.59 | 10.62 | 9.02 | 9.18 | -12.65% | 94,414,400 | |
| 05 Oct 2026 – 09 Oct 2026 | 10.76 | 10.81 | 9.33 | 10.51 | +2.19% | 74,683,500 | |
| 28 Sep 2026 – 02 Oct 2026 | 8.39 | 10.55 | 8.26 | 10.29 | +21.86% | 89,632,300 | |
| 21 Sep 2026 – 25 Sep 2026 | 8.72 | 9.48 | 8.26 | 8.44 | -0.47% | 62,125,300 | |
| 14 Sep 2026 – 18 Sep 2026 | 7.89 | 8.80 | 7.76 | 8.48 | +7.21% | 64,900,800 | |
| 08 Sep 2026 – 11 Sep 2026 | 8.00 | 8.37 | 7.64 | 7.91 | -2.10% | 38,487,200 | |
| 252 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- IBRX Stock Eyes Best Year Ever: Founder Teases 12 Months Of ‘Stealth’ NantWorks Reveals — Cancer Tech, AI Chips And Satellites (opens in a new tab) Stocktwits · 13 Nov 2026 01:20
- ImmunityBio (IBRX) is Declining For 4 Days Now. What’s Triggering the Selloff? (opens in a new tab) Insider Monkey · 13 Nov 2026 00:48
- IBRX Stock Eyes Worst Week In Nearly 2 Years — But Anktiva’s Sepsis Trial Potential Fuels Retail Bets On Big Pharma Appeal (opens in a new tab) Stocktwits · 12 Nov 2026 03:52
- What Could ImmunityBio (IBRX) Gain From ANKTIVA Label Expansion And Global Rollout? (opens in a new tab) Simply Wall St. · 12 Nov 2026 02:15
- ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026 (opens in a new tab) 11 Nov 2026 02:31
- IBRX Q3 Earnings Miss, Anktiva Sales Decline Q/Q, Stock Down 18% (opens in a new tab) Zacks · 10 Nov 2026 14:03
- Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy? (opens in a new tab) Motley Fool · 09 Nov 2026 20:38
- ImmunityBio shares slump 19% as revenue misses and going-concern warning hits sentiment (opens in a new tab) Proactive · 09 Nov 2026 16:44
- IBRX Stock Crashes To Near 9-Month Lows On Q3 Earnings Miss – Retail Says No Way To Escape Further Dilution (opens in a new tab) Stocktwits · 09 Nov 2026 14:36
- ImmunityBio (IBRX) Reports Q3 Loss, Misses Revenue Estimates (opens in a new tab) Zacks · 09 Nov 2026 12:50
- ImmunityBio: Q3 Earnings Snapshot (opens in a new tab) Associated Press · 09 Nov 2026 12:37
- ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million (opens in a new tab) 09 Nov 2026 12:30
- ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ (opens in a new tab) 09 Nov 2026 12:00
- ImmunityBio Reports Wider Quarterly Loss (opens in a new tab) Benzinga · 09 Nov 2026 11:31
- ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial (opens in a new tab) 09 Nov 2026 11:30
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 6.07 USD
- Market cap
- 6.5B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow IBRX and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.